Using molecular radiogenomics to improve treatment predictions in lung cancer
The Use of Molecular Radiogenomics in Non-small Cell Lung Cancer
This study is testing if combining special imaging and genetic information can help doctors better predict how well treatments will work for people with non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Buddhist Tzu Chi General Hospital Academic / other |
| Locations | 1 site (Hualien City) |
| Trial ID | NCT05541744 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related deaths. The researchers aim to combine molecular imaging techniques, specifically 18F-FDG PET, with whole exome sequencing to create a more accurate model for predicting treatment responses and survival outcomes. By analyzing tumor biology and genetic alterations, the study seeks to enhance risk stratification for patients undergoing treatment. The study utilizes routine pathological specimens and advanced sequencing technologies to gather comprehensive data on tumor characteristics.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 20 years and older with a pathological diagnosis of non-small cell lung cancer who have undergone complete staging.
Not a fit: Patients with other concurrent cancers or those unable to undergo FDG PET/CT imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans and improved survival rates for lung cancer patients.
How similar studies have performed: While the combination of radiogenomics is a novel approach, similar studies have shown promise in enhancing predictive models for cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age at least 20-years * Pathological proven non-small cell lung cancer and received complete staging work-up * Pre-treatment pathological specimen of the primary tumor Exclusion Criteria: * Coexistence of non-aerodigestive tract cancer. * Unable to comply to FDG PET/CT exam or poor image quality * Unable to determine the primary tumor
Where this trial is running
Hualien City
- Hualien Tzu Chi Hospital — Hualien City, Taiwan (Recruiting)
Study contacts
- Study coordinator: Yu-Hung Chen, M.D.
- Email: jedimasterchen@hotmail.com
- Phone: 886-3-8561825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.